Respiratory Virus Vaccines – Recent Update

We would like to invite you to this special in-person education session.

Light lunch and refreshments will be provided. Please note: this event will not be streamed live, but will be recorded and available after the event on the BC-CfE’s website at: education.bccfe.ca/webinars.

Cost: Free registration.

Speaker:

Danuta M Skowronski MD, FRCPC


At the end of the webinar, participants will be able to:

  • Address unique considerations in the monitoring of select respiratory viruses (e.g. RSV, SARS-CoV-2, influenza)
  • Understand approaches to evaluating vaccine performance real-time
  • Review issues important to vaccine program decision-making

Please note:

Presentations will be followed by a discussion where participants will have the opportunity to ask questions and receive real-time responses from presenters.

This event is accredited by the College of Family Physicians of Canada and the British Columbia Chapter for up to 1 Mainpro+ credit.

Please register for the lecture by clicking the following link:

click here.

Please send any questions to education@bccfe.ca. We are looking forward to seeing you there!

Event Details

Days
Hours
Minutes
Seconds
Start Date
End Date
Event Category
Attendees of the BC-CfE Learning Series will be able to:
  • Summarize and describe epidemiological, behavioural, virological, and other related research relevant to the management of people living with HIV and other syndemic conditions
  • Describe and demonstrate up-to-date information regarding the care of people living with HIV and syndemic conditions (including viral hepatitis and substance use) particularly in regards to primary care, antiretroviral therapy and other treatments, and comorbid conditions
  • Review new and emerging issues in the context of the management of people living with HIV and other syndemic conditions
  • Identify both clinical and community resources to support the care of people living with HIV and syndemic conditions.
Scroll to Top

The British Columbia Centre for Excellence in HIV/AIDS Laboratory has discontinued gp-41 resistance testing as T-20 (enfuvirtide/Fuzeon) is no longer available in Canada as of March 31, 2025